General Health Panel
The General Health Panel is utilized by the physician to diagnose illness or to help monitor the patient’s response to treatment. GHP provides a general look at the patient’s wellbeing. The GHP is performed most commonly during normal health screenings or when a disease is suspected in order to obtain general information that may be useful in diagnosis. The most common tests included in this panel are Complete Blood Count (CBC), Complete Metabolic Panel (CMP), and Thyroid Stimulating Hormone (TSH). It is commonly ordered at an annual physical examination or checkup, as supportive diagnostic testing for a wide range of diseases and syndromes, for disease management, therapy monitoring, and patient safety during therapy, and during any medical intervention and post-therapy as well as drug side effect monitoring.
Any abnormal results in any of these tests or in combination may provide an important initial indication of a disease state; the differential diagnosis of that state might then indicate more specialized testing to be ordered. Because this panel contains the main metabolic monitoring tests, this panel usually provides an important screening check on the status of kidney and kidney function, liver and liver function, heart and heart status, electrolyte and body fluid balance, and other body systems.
It is routinely used to monitor the status of a patient with a chronic disease such as a chronic autoimmune disease, diabetes mellitus, hypertension, cancer, chronic infection, and inflammation.
This test does not meet "medical necessity" so labs need to “unbundle” the group of tests to make them billable.
- Since this panel has a broad use, we list here only the major utilities of this panel:
- As an aid in diagnosis of chronic diseases (autoimmune diseases, diabetes etc.)
- Inflammation
- Infections
- Blood disorders
- Kidney diseases
- Urinary tract diseases
- Liver diseases
- Gastrointestinal diseases
- Cardiovascular system disorders
- Heart disease
- Hypertension
- Bone diseases
- Muscle disorders
- Cancers
- Congenital disorders
- Genetic disorders
- Use as a screening test for physical evaluation
- Disease management and therapy monitoring
- Safety monitoring during therapy
- Supportive testing for many medical interventions
Abnormal results (both increases and decreases) of one or more can be significant and might indicate the need for additional disease or disorder specialized testing.
- Chronic diseases (autoimmune diseases, diabetes)
- Inflammation
- Trauma and burns
- Infections
- Blood disorders
- Kidney diseases
- Liver diseases
- Gastrointestinal diseases
- Cardiovascular system disorders
- Disease related to the heart
- Hypertension
- Bone diseases
- Muscle disorders
- Cancer
- Congenital disorders
- Genetic disorders
- Pancreatic diseases
- Storage disorders
- Surgery
- Pregnancy
- Poisoning
- Enzyme metabolic diseases
- Myeloproliferative disorders
- Hemoconcentration due to dehydration
- Anemia
- Bleeding
- Hemolytic anemias
- Spurious decrease with autoagglutination (e.g., cold agglutinins)
Note: for more information see individual test utility and interpretation.
Uric Acid (Blood):
3.0 and 7.0 mg/dL
Uric Acid (Urine):
250-800 mg/24 hours
Thyroid-Stimulating Hormone (TSH):
0.4 - 4.0 mIU/L
Lactate Dehydrogenase (LDH):
105 - 333 IU/L
Gamma-Glutamyl Transpeptidase (GGT):
0-51 IU/L
Complete Blood Count (CBC):
WBC: 4.5-11 x 103 cells/mm3
RBC: 4.5-5.9 x 106/mm3 (male)
4-5.2 x 106/mm3 (female)
MCV: 80-100 mcm3
MCHC: 31-37 g/dL
Hgb: 13.5-17.5 g/dL (male)
12-16 g/dL (female)
Hct: 41%-53% (male)
36%-46% (female)
Platelet Count: 150-350 × 103 /mm3
Differential Blood Count:
Neutrophils: 3150 to 6200/uL
Lymphocytes: 1500 to 3000/uL
Monocytes: 300 to 500/uL
Eosinophils: 50 to 250/uL
Basophils: 15 to 50/uL
Serum (SST), Plasma (EDTA).
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- Journal of Occupational and Environmental Medicine. 2003;45 (10): 1049–57. doi:10.1097/01.jom.0000088875.85321.b9. [PMID: 14534445]
- Urol Int. 2007;79 Suppl 1:20-5. [PMID: 17726348]
- Clin Nutr. 2001;20:477. [PMID: 11883995]
- J Am Diet Assoc. 2004;104:1258. [PMID: 15281044]
- Addict Behav. 2004;29:1427. [PMID: 15345274]
- Biochem. 1995 Feb;28(1):1-29. [PMID: 7720223]
- Clin Med. 2002 Sep-Oct;2(5):406-9. [PMID: 12448585]
- Clin Gastroenterol Hepatol. 2005;3:852. [PMID: 16234021]
- CMAJ. 2005;172:367. [PMID: 15684121]
- Am Fam Physician. 1992 Mar;45(3):1139-48. [PMID: 1543099]
- Am Fam Physician. 2004;69:299. [PMID: 14765767]
- Clin Lab Med. 2002;22:377. [PMID: 12134466]
- Thromb Haemost. 2002;87:74. [PMID: 11848460]
- J Thromb Haemost. 2006;4:967. [PMID: 16689743]
- Clin Lab Med. 1993 Mar;13(1):117-29 [PMID: 8462254]
- Acta Med Indones. 2007 Jul-Sep;39(3):145-50 [PMID: 17936961]
- Am Fam Physician. 2005;72:1723. [PMID: 16300034]
- N Engl J Med. 1983;309:925. [PMID: 6888491]
- Mayo Clin Proc. 2005;80:923. [PMID: 16007898]
- Harmening DM. Clinical Hematology and Fundamentals of Hemostasis 3rd edition. Philadelphia: F.A. Davis Company (1997).